Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 3,733 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 3,733 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33. Following the transaction, the insider directly owned 4,275,693 shares in the company, valued at approximately $29,972,607.93. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Up 0.7%

Shares of TRDA traded up $0.05 during trading hours on Monday, reaching $7.05. 450,412 shares of the company traded hands, compared to its average volume of 325,154. Entrada Therapeutics, Inc. has a 12 month low of $5.02 and a 12 month high of $16.45. The company’s fifty day moving average price is $7.08 and its two-hundred day moving average price is $9.31. The company has a market capitalization of $274.51 million, a price-to-earnings ratio of -1.78 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Several large investors have recently made changes to their positions in the business. State of Wyoming bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $37,000. Russell Investments Group Ltd. increased its position in Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new position in Entrada Therapeutics during the second quarter valued at $68,000. IHT Wealth Management LLC purchased a new position in Entrada Therapeutics during the second quarter valued at $72,000. Finally, Jain Global LLC purchased a new position in Entrada Therapeutics during the third quarter valued at $69,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on TRDA shares. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Roth Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Weiss Ratings lowered Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.